P416 Results of the first paediatric randomised controlled trial of faecal microbiota transplant for ulcerative colitis
ECCO'20 Vienna
2020
P417 Do ACE inhibitors and angiotensin II receptor blockers improve disease outcomes in inflammatory bowel disease?
ECCO'20 Vienna
2020
P418 Filgotinib decreases molecular markers of JAK1 signal transduction in Crohn’s disease: concordance with endoscopy and histopathology
ECCO'20 Vienna
2020
P420 A randomised, observer-blinded phase Ib multiple, ascending dose study of UTTR1147A, an IL-22Fc fusion protein, in healthy volunteers and ulcerative colitis patients
ECCO'20 Vienna
2020
P421 Prognostic and therapeutic long-term outcome of patients with ulcerative proctitis: analysis from a large referral centre cohort study
ECCO'20 Vienna
2020
P422 Tofacitinib induces clinical and endoscopic remission in biologic refractory ulcerative colitis patients: a real-world Belgian cohort study
ECCO'20 Vienna
2020
P423 NF-kB as a prognostic marker of response to biologic therapy in children with IBD
ECCO'20 Vienna
2020
P424 Economic evaluation of vedolizumab SC for the treatment of moderate-to-severe ulcerative colitis in Canada
ECCO'20 Vienna
2020
P425 SPOSIB SB2: a Sicilian prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar SB2
ECCO'20 Vienna
2020
P427 A hybrid approach of handling missing data in inflammatory bowel disease (IBD) trials: results from VISIBLE 1 and VARSITY
ECCO'20 Vienna
2020
P428 Oral mesalamine use in Crohn’s disease after implementation of the American College of Gastroenterology guidelines: a TARGET-IBD cohort study
ECCO'20 Vienna
2020
P429 Clinical utility of thiopurine metabolite monitoring in inflammatory bowel disease and its impact on healthcare utilisation in Singapore
ECCO'20 Vienna
2020
P430 Feasibility and reliability of gastrointestinal ultrasound in pregnant inflammatory bowel disease patients
ECCO'20 Vienna
2020
P432 Effects and safety of a colon-long absorbing budesonide product in patients with mild to moderate ulcerative colitis
ECCO'20 Vienna
2020